Fibrobiologics, Common Stock Stock Market Value
| FBLG Stock | 2.15 0.01 0.46% |
| Symbol | FibroBiologics, |
FibroBiologics, Common Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of FibroBiologics, Common. If investors know FibroBiologics, will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about FibroBiologics, Common listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.55) | Return On Assets (0.66) | Return On Equity (2.68) |
The market value of FibroBiologics, Common is measured differently than its book value, which is the value of FibroBiologics, that is recorded on the company's balance sheet. Investors also form their own opinion of FibroBiologics, Common's value that differs from its market value or its book value, called intrinsic value, which is FibroBiologics, Common's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because FibroBiologics, Common's market value can be influenced by many factors that don't directly affect FibroBiologics, Common's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between FibroBiologics, Common's value and its price as these two are different measures arrived at by different means. Investors typically determine if FibroBiologics, Common is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, FibroBiologics, Common's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
FibroBiologics, Common 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to FibroBiologics, Common's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of FibroBiologics, Common.
| 05/28/2023 |
| 12/18/2024 |
If you would invest 0.00 in FibroBiologics, Common on May 28, 2023 and sell it all today you would earn a total of 0.00 from holding FibroBiologics, Common Stock or generate 0.0% return on investment in FibroBiologics, Common over 570 days. FibroBiologics, Common is related to or competes with ReTo Eco, MYR, Newpark Resources, Cementos Pacasmayo, RBC Bearings, and Nabors Industries. FibroBiologics, Common is entity of United States More
FibroBiologics, Common Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure FibroBiologics, Common's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess FibroBiologics, Common Stock upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.08) | |||
| Maximum Drawdown | 31.15 | |||
| Value At Risk | (9.73) | |||
| Potential Upside | 10.15 |
FibroBiologics, Common Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for FibroBiologics, Common's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as FibroBiologics, Common's standard deviation. In reality, there are many statistical measures that can use FibroBiologics, Common historical prices to predict the future FibroBiologics, Common's volatility.| Risk Adjusted Performance | (0.04) | |||
| Jensen Alpha | (0.66) | |||
| Total Risk Alpha | (0.94) | |||
| Treynor Ratio | (0.11) |
FibroBiologics, Common Backtested Returns
FibroBiologics, Common secures Sharpe Ratio (or Efficiency) of -0.0613, which denotes the company had a -0.0613% return per unit of standard deviation over the last 3 months. FibroBiologics, Common Stock exposes twenty-one different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm FibroBiologics, Common's Coefficient Of Variation of (1,506), mean deviation of 4.93, and Standard Deviation of 6.39 to check the risk estimate we provide. The firm shows a Beta (market volatility) of 3.99, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, FibroBiologics, Common will likely underperform. At this point, FibroBiologics, Common has a negative expected return of -0.4%. Please make sure to confirm FibroBiologics, Common's standard deviation, potential upside, day median price, as well as the relationship between the jensen alpha and accumulation distribution , to decide if FibroBiologics, Common performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.08 |
Virtually no predictability
FibroBiologics, Common Stock has virtually no predictability. Overlapping area represents the amount of predictability between FibroBiologics, Common time series from 28th of May 2023 to 8th of March 2024 and 8th of March 2024 to 18th of December 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of FibroBiologics, Common price movement. The serial correlation of 0.08 indicates that barely 8.0% of current FibroBiologics, Common price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.08 | |
| Spearman Rank Test | 0.23 | |
| Residual Average | 0.0 | |
| Price Variance | 0.57 |
FibroBiologics, Common lagged returns against current returns
Autocorrelation, which is FibroBiologics, Common stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting FibroBiologics, Common's stock expected returns. We can calculate the autocorrelation of FibroBiologics, Common returns to help us make a trade decision. For example, suppose you find that FibroBiologics, Common has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
FibroBiologics, Common regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If FibroBiologics, Common stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if FibroBiologics, Common stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in FibroBiologics, Common stock over time.
Current vs Lagged Prices |
| Timeline |
FibroBiologics, Common Lagged Returns
When evaluating FibroBiologics, Common's market value, investors can use the concept of autocorrelation to see how much of an impact past prices of FibroBiologics, Common stock have on its future price. FibroBiologics, Common autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, FibroBiologics, Common autocorrelation shows the relationship between FibroBiologics, Common stock current value and its past values and can show if there is a momentum factor associated with investing in FibroBiologics, Common Stock.
Regressed Prices |
| Timeline |
Currently Active Assets on Macroaxis
When determining whether FibroBiologics, Common is a strong investment it is important to analyze FibroBiologics, Common's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact FibroBiologics, Common's future performance. For an informed investment choice regarding FibroBiologics, Stock, refer to the following important reports:Check out FibroBiologics, Common Correlation, FibroBiologics, Common Volatility and FibroBiologics, Common Alpha and Beta module to complement your research on FibroBiologics, Common. You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
FibroBiologics, Common technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.